Department of Obstetrics and Pathology of Pregnancy, Medical University of Lublin, 20-059 Lublin, Poland.
Department of Molecular Virology, Institute of Experimental Biology, Adam Mickiewicz University in Poznan, 61-712 Poznań, Poland.
Cells. 2024 Mar 26;13(7):580. doi: 10.3390/cells13070580.
Previous research indicates that carcinogenesis involves disrupting the functions of numerous genes, including factors involved in the regulation of transcription and cell proliferation. For these reasons, in endometrial carcinogenesis, we decided to investigate the expression of TSG101 (a suppressor of tumor transformation) and LSF (a transcription factor involved in numerous cellular processes, such as cell cycle regulation, cell growth, development, and apoptosis). LSF may be involved in the regulation of TSG101 expression. The research material consisted of endometrial cancer samples from 60 patients. The control group consisted of normal endometrium samples donated by 60 women undergoing surgery for benign diseases of the female reproductive organs. The samples were subjected to immunohistochemical staining with antibodies specific to TSG101 and LSF. Specific antibodies were used to identify TSG101 and LSF in the examined histopathological preparations. An approximately 14-fold lower risk of endometrial cancer development was observed in patients with TSG expression in more than 75% of the assessed cells (4% vs. 36%; OR = 0.07; = 0.0182). There was a four-fold lower risk of endometrial cancer development in patients with LSF expression in more than 50% of the assessed cells (32% vs. 64%; OR = 0.26; = 0.0262). A more than three-fold lower risk of endometrial cancer development was observed in patients with LSF expression in more than 75% of the assessed cells (24% vs. 52%; OR = 0.29; = 0.0454). Endometrial cancer was diagnosed in those with a lower level of TSG101 expression than in those with a cancer-free endometrium. Decreased expression of TSG101 may be a marker of endometrial cancer, and increased expression of LSF when diagnosed with endometrial cancer may indicate greater advancement of the disease. These markers might be used as diagnostic and prognostic markers-however, there is a lack of a correlation between them.
先前的研究表明，癌变涉及破坏众多基因的功能，包括参与转录和细胞增殖调节的因子。基于这些原因，在子宫内膜癌变中，我们决定研究 TSG101（肿瘤转化的抑制剂）和 LSF（参与众多细胞过程的转录因子，如细胞周期调节、细胞生长、发育和细胞凋亡）的表达。LSF 可能参与 TSG101 表达的调节。研究材料由 60 名患者的子宫内膜癌样本组成。对照组由 60 名因女性生殖器官良性疾病接受手术的妇女捐赠的正常子宫内膜样本组成。对这些样本进行 TSG101 和 LSF 特异性抗体的免疫组织化学染色。使用特定的抗体来鉴定在检查的组织病理学制剂中 TSG101 和 LSF。在 TSG 表达超过 75%评估细胞的患者中，子宫内膜癌发展的风险降低了约 14 倍（4%对 36%；OR=0.07；=0.0182）。在 LSF 表达超过 50%评估细胞的患者中，子宫内膜癌发展的风险降低了约 4 倍（32%对 64%；OR=0.26；=0.0262）。在 LSF 表达超过 75%评估细胞的患者中，子宫内膜癌发展的风险降低了约 3 倍（24%对 52%；OR=0.29；=0.0454）。与无子宫内膜癌的患者相比，TSG101 表达水平较低的患者被诊断为子宫内膜癌。TSG101 表达降低可能是子宫内膜癌的标志物，在诊断为子宫内膜癌时 LSF 表达增加可能表明疾病进展更大。这些标志物可以用作诊断和预后标志物-但是，它们之间缺乏相关性。
